Európska únia - španielčina - EMA (European Medicines Agency)

akcea therapeutics ireland limited - inotersen de sodio - amilosis - otras drogas del sistema nervioso - tratamiento de la fase 1 o fase 2 polineuropatía en pacientes adultos con hereditario transtiretina amiloidosis (hattr).

Peru - španielčina - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pfizer s.a. - droguerÍa - mnb rlp 2086 subfamilia a mnb rlp2086 subfamilia b - suspension inyectable - por dosis 0.50 ml - - meningococo b, vacuna multicomponente

Európska únia - španielčina - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - agentes modificadores de lípidos - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Európska únia - španielčina - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsia - los antiepilépticos, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Európska únia - španielčina - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - terapia biliar y hepática - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 y 5.

Európska únia - španielčina - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hipercolesterolemia - agentes modificadores de lípidos - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Čile - španielčina - ISPC (Instituto de Salud Pública de Chile)

cosmÉticos avon s.a. - sin formulas

Čile - španielčina - ISPC (Instituto de Salud Pública de Chile)

cosmÉticos avon s.a. - sin formulas

Čile - španielčina - ISPC (Instituto de Salud Pública de Chile)

cosmÉticos avon s.a. - sin formulas

Čile - španielčina - ISPC (Instituto de Salud Pública de Chile)

laboratorio ballerina ltda. - sin formulas